CRSP CRISPR: Price-to-Projected Revenue Ratio

Official company branding of CRISPR Therapeutics (CRSP)

The forward price-to-sales valuation trend shows that the parameter reaches 154.80. Management under Samarthit Chatterjee has successfully launched the first gene therapy on the market while maintaining high liquidity for CRISPR Therapeutics AG (CRSP). Asset value growth now relies on the implementation of Casgevy and achievements in immuno-oncology. A strategic alliance with pharmaceutical behemoths provides scientific synergy and capital for the development of DNA technologies.

CRISPR Therapeutics - CRSP Forward P/S Multiple (period 07/04/2022 - 11/18/2026)

CRSP (CRISPR Therapeutics): analytical breakdowns and indicator data

- current price and projected stock value:
Fundamental company analysis:CRISPR Therapeutics (CRSP)
Product sample of crisprtx.com

The forward P/S ratio assesses the market value of an asset relative to expected revenue, allowing investors to determine the extent of the premium paid for future cash flows. By analyzing the expected P/S chart for CRISPR Therapeutics AG (CRSP), one can evaluate how effectively the capitalization reflects the potential of the R&D core, comprised of elite geneticists whose DNA editing developments determine the long-term commercial value of the business.

Competing companies

Forward P/S Multiple TEM (Tempus Labs)|Qiagen N.V. - Price-to-Projected Revenue Ratio|IONS - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio repligen.com|RNA: Forward P/S Multiple|Market Cap to Projected Revenue WGS|RARE (Ultragenyx Pharma) - Forward P/S Multiple|Forward P/S Multiple Beam Therapeutics Inc.|Price-to-Projected Revenue Ratio Sarepta Therapeutics Inc (SRPT)|Twist Bioscience - Market Cap to Projected Revenue|10x Genomics Inc - Forward Price-to-Revenue Multiple|NTLA (Intellia Therapeutics, Inc.) - Future Price to Revenue|Stoke Corp - Forward P/S Multiple|BLFS (BioLife) - Market Cap to Projected Revenue|wavelifesciences.com (WVE) - Price-to-Projected Revenue Ratio|MAZE - Market Cap to Expected Sales Ratio|SION (Sionna Therapeutics, Inc.) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Prime Medicine Corp (PRME)|Forward P/S Multiple TSHA|Forward P/S Multiple uniQure N.V. (QURE)|Price-to-Projected Revenue Ratio MeiraGTx Holdings plc MGTX|RGNX: Market Cap to Projected Revenue|Solid Biosciences Inc - Forward P/S Multiple|OCGN - Forward P/S Multiple|PACB: Forward P/S Multiple|BNTC - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Design Therapeutics, Inc.|RCKT: Forward Price to Sales|Forward Price-to-Revenue Multiple FDMT (4D Molecular Therapeutics, Inc.)|Lexeo Therapeutics, Inc. - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Korro Bio, Inc. KRRO|EDIT: Market Cap to Projected Revenue|SLN - Price-to-Projected Revenue Ratio|Projected Price to Revenue ProQR Therapeutics (PRQR)|CDXS (Codexis Bio) - Forward Price-to-Revenue Multiple|Sangamo Therapeutics Inc. (SGMO) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Nautilus Bio|Market Cap to Future Revenue Ratio Metagenomi Therapeutics MGX|Price-to-Projected Revenue Ratio Precision BioSciences (DTIL)|GBIO - Market Cap to Future Revenue Ratio|Forward P/S Multiple BOLD (Boundless Bio, Inc)|XCUR - Forward Price-to-Revenue Multiple|IMNN - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Phio Pharmaceuticals Corp|MBIO: Forward P/S Multiple|TransCode (RNAZ) - Forward P/S Multiple|BNGO (Bionano) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Applied DNA Sciences, Inc. APDN|Forward P/S Multiple BLUE|ImmunoPrecise Antibodies Ltd - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Omega Therapeutics OMGA|OMIC: Market Cap to Projected Revenue|RGLS: Forward Price-to-Revenue Multiple|Forward Price to Sales SYRS (Syros Pharmaceuticals, Inc.)|Telesis Bio, Inc. (TBIO) - Price-to-Projected Revenue Ratio|Future Price to Revenue TCON (TRACON)|Price-to-Projected Revenue Ratio Unity Biotechnology, Inc.